AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting
SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time, ImmVira presented preclinical study results of CAR-T enabler oHSV product MVR-7011 through poster publication at the American Association for Cancer Research ("AACR") annual meeting.
- SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time, ImmVira presented preclinical study results of CAR-T enabler oHSV product MVR-7011 through poster publication at the American Association for Cancer Research ("AACR") annual meeting.
- A breakthrough advantage is that current CAR-T therapies originally targeting blood cancer can be enabled on solid tumors without any modifications required.
- At the AACR meeting, ImmVira presented the main preclinical study results of MVR-T7011 for the first time.
- ImmVira has completed in-house pilot-scale manufacturing of MVR-T7011 and launched preclinical study.